Anti-CGRP Drugs for Intractable Chronic Daily Headache: When Other Treatments Fail
Anti-CGRP medications showed effectiveness in managing intractable chronic daily headache that had not responded to other preventive treatments, offering hope for the most refractory patients.
Quick Facts
What This Study Found
Anti-CGRP medications effectively reduced headache frequency and severity in patients with intractable chronic daily headache refractory to other preventive treatments.
Key Numbers
All consecutive patients under 18 years at a single center. All had failed multiple daily preventive medications.
How They Did This
Clinical evaluation of anti-CGRP medications (mAbs and gepants) in patients with intractable CDH who failed multiple prior preventive therapies.
Why This Research Matters
Patients with intractable CDH suffer daily and have exhausted standard treatments. Anti-CGRP drugs offer a lifeline by targeting a different pathway than previous failed therapies.
The Bigger Picture
CGRP-targeting drugs are increasingly positioned as the best option for the hardest-to-treat headache patients. Moving from episodic migraine to chronic migraine to intractable CDH, the evidence supports CGRP drugs across the entire severity spectrum.
What This Study Doesn't Tell Us
Intractable CDH is heterogeneous. Response rates may be lower than in less refractory populations. Lack of placebo control in refractory settings. Small sample sizes typical for treatment-resistant populations.
Questions This Raises
- ?Which anti-CGRP drug is most effective for the most refractory CDH patients?
- ?Should anti-CGRP drugs be tried earlier in CDH before other preventives fail?
- ?Can combining anti-CGRP mAbs with gepants provide additional benefit in refractory CDH?
Trust & Context
- Key Stat:
- Last-line success Anti-CGRP drugs worked in patients with chronic daily headache that had failed multiple other preventive treatments
- Evidence Grade:
- Moderate evidence: clinical evaluation in a refractory population where controlled trials are difficult to conduct.
- Study Age:
- Published in 2025. Extends anti-CGRP evidence to the most treatment-resistant headache patients.
- Original Title:
- The Use of Anti-CGRP Medications for Management of Intractable Chronic Daily Headaches in the Pediatric Population: Case Series and Literature Review.
- Published In:
- Journal of child neurology, 8830738251374537 (2025)
- Authors:
- Akbar, Asra, Deshpande, Girish, Tripathi, Sandeep
- Database ID:
- RPEP-09809
Evidence Hierarchy
Frequently Asked Questions
What options are left when headache treatments fail?
Anti-CGRP drugs (antibodies like erenumab/fremanezumab and oral gepants like rimegepant) target a different pathway than most previous treatments. This study shows they work even in the most treatment-resistant chronic daily headache patients.
Are anti-CGRP drugs stronger than other headache treatments?
Not necessarily stronger, but different. They target the CGRP pathway specifically, which other preventive treatments do not. This means they can work when everything else has failed because they address a mechanism those other drugs missed.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09809APA
Akbar, Asra; Deshpande, Girish; Tripathi, Sandeep. (2025). The Use of Anti-CGRP Medications for Management of Intractable Chronic Daily Headaches in the Pediatric Population: Case Series and Literature Review.. Journal of child neurology, 8830738251374537. https://doi.org/10.1177/08830738251374537
MLA
Akbar, Asra, et al. "The Use of Anti-CGRP Medications for Management of Intractable Chronic Daily Headaches in the Pediatric Population: Case Series and Literature Review.." Journal of child neurology, 2025. https://doi.org/10.1177/08830738251374537
RethinkPeptides
RethinkPeptides Research Database. "The Use of Anti-CGRP Medications for Management of Intractab..." RPEP-09809. Retrieved from https://rethinkpeptides.com/research/akbar-2025-the-use-of-anticgrp
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.